Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp. reports developments in healthcare market data, analytics, and commercial intelligence for organizations operating on the business side of healthcare. Its SaaS-based platform and related solutions support use cases such as market selection, go-to-market planning, provider targeting, affiliation analysis, prescription-pattern visibility, Key Opinion Leader identification, and workflow data enrichment.
Recurring news for DH includes quarterly and annual financial results, guidance commentary, customer wins and renewals across life sciences and health-system markets, expansions involving products such as Monocl and Population Intelligence, data-integration use cases, and investor conference presentations. Company updates also describe subscription revenue trends, adjusted profitability measures, cash flow, and commercial execution across new logos and existing customers.
Definitive Healthcare Corp. (Nasdaq: DH) announced that its Chief Financial Officer, Rick Booth, will present at the Raymond James 2023 Institutional Investors Conference on March 7, 2023, at 2:50 p.m. Eastern Time. Investors can access a live webcast of the presentation on the Definitive Healthcare investor relations website. A replay will also be available for a limited time.
Definitive Healthcare is a leader in healthcare commercial intelligence, transforming data and analytics to help clients identify market opportunities. To learn more, visit definitivehc.com.
Definitive Healthcare reported a strong performance for Q4 and full year 2022, with revenue growth of 31% to $60.6 million in Q4, and a 34% increase to $222.7 million for the year. GAAP net income improved to $6.7 million, contrasting with a loss of $14.8 million in Q4 2021. Adjusted net income also rose to $10.5 million. For 2023, the company anticipates revenue between $249.0 million and $255.0 million, reflecting a 14% year-over-year increase. The launch of the Atlas Dataset and several key customer contracts signify substantial growth potential in the healthcare intelligence market.
GovForce, a technology company focused on government contractors, has secured $2.5 million in seed equity funding led by QED Investors and Humba Ventures. This funding aims to enhance its software platform designed to assist prime contractors with performance monitoring and compliance management. With government contractors managing approximately $700 billion annually in federal contracts, effective compliance is crucial. The GovForce platform addresses heightened security and reporting challenges in the industry, streamlining processes for subcontractor management, ultimately improving efficiency and performance.
Definitive Healthcare (Nasdaq: DH) announced it will release its fourth quarter and full year financial results on February 23, 2023, after market close. The company will hold a conference call at 5:00 PM ET to discuss the results. Investors can listen to the event via a live audio webcast on the Definitive Healthcare Investor Relations website. The replay of the call will be available until March 9, 2023, for those who cannot attend the live session.
Definitive Healthcare specializes in healthcare commercial intelligence, aiding clients in identifying market opportunities.
Definitive Healthcare (Nasdaq: DH) announced the launch of its Atlas Dataset, a comprehensive resource for healthcare commercial intelligence. This dataset integrates information on over 15 million healthcare professionals and 300,000 organizations, positioning it as a leading tool for clients to make informed decisions. An independent survey indicated the dataset's top ranking for reference and affiliation data. It includes key components such as Atlas Reference & Affiliation, All-Payor Claims, and Prescription Claims, enhancing visibility into healthcare operations and contributing to improved market understanding.
Definitive Healthcare (Nasdaq: DH) reported a 60% increase in its Atlas Prescription Claims and significant growth in Atlas All-Payor Claims. This expansion enhances data for healthcare providers to improve patient outcomes, particularly in areas like rare diseases and oncology, with nearly 20% increases in these sectors. CEO Robert Musslewhite emphasized the value of the expanded dataset for driving commercial success, refining methodologies, and increasing patient cohort accuracy. The updated Atlas Dataset equips clients with comprehensive insights into patient care, provider behavior, and market trends.
Definitive Healthcare Corp. (Nasdaq: DH) announced its participation in the 25th Annual Needham Growth Conference. CEO Robert Musslewhite and CFO Rick Booth will present on January 11, 2023, at 11:00 a.m. ET. Interested parties can access the live webcast via the Definitive Healthcare investor relations website.
The company is recognized for its healthcare commercial intelligence, using data and analytics to assist clients in navigating market opportunities effectively.
Definitive Healthcare (Nasdaq: DH) has been recognized as one of the Top Places to Work in Massachusetts for the sixth consecutive year by The Boston Globe. The award is based on surveys of employee satisfaction, assessing factors like leadership and workplace culture. CEO Robert Musslewhite highlighted the company’s commitment to an inclusive culture and employee development. Additionally, Definitive Healthcare was named a Top Workplace in the United States by Energage. The company actively promotes diversity and engages in community support through its DefinitiveCares initiative.
Definitive Healthcare Corp. (Nasdaq: DH) has appointed Jon Maack as President effective November 3, 2022. Maack, who brings extensive experience in healthcare SaaS, will oversee product management, engineering, corporate strategy, and M&A, reporting to CEO Robert Musslewhite. Maack previously served as Chief Strategy Officer at athenahealth and held senior roles at Optum and Bain & Company. He expressed excitement about joining Definitive Healthcare, emphasizing the untapped potential in the healthcare commercial intelligence market as they aim to enhance tools for their customer base of over 3,000.
Definitive Healthcare Corp. (Nasdaq: DH) reported a 33% year-over-year revenue growth to $57.4 million for Q3 2022. The net loss narrowed to ($6.4) million from ($21.0) million in Q3 2021, representing 11% of revenue. Adjusted net income rose to $8.9 million with adjusted EBITDA at $16.4 million, or 29% of revenue. The company continues to gain traction with new customers and product launches, including Passport Express. For Q4 2022, it expects revenue between $58-59 million, a 26% increase year-over-year.